Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Baxter
Boehringer Ingelheim
Harvard Business School
Express Scripts

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Litigation Details for Osmotica Pharmaceutical US LLC v. Adamas Pharmaceuticals, Inc. (D. Del. 2018)

See Plans and Pricing

« Back to Dashboard

Osmotica Pharmaceutical US LLC v. Adamas Pharmaceuticals, Inc. (D. Del. 2018)

Docket   Start Trial Date Filed 2018-02-16
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand Plaintiff Referred To
Parties ADAMAS PHARMA, LLC; ADAMAS PHARMACEUTICALS, INC.; OSMOTICA PHARMACEUTICAL US LLC; VERTICAL PHARMACEUTICALS, LLC
Patents 8,389,578; 8,741,343; 8,796,337; 8,889,740; 8,895,614; 8,895,615; 8,895,616; 8,895,617; 8,895,618; 9,867,791; 9,867,792; 9,867,793
Attorneys Adam LaRock; Adam Wyatt Poff; Alison Mulry; Bruce M. Wexler; Charles T. Wysocki; Dennies Varughese; Isaac S. Ashkenazi; Jack B. Blumenfeld; Jeremy A. Tigan; Matthew M. Zuziak; Pilar Gabrielle Kraman; Scott F. Peachman
Firms Morris, Nichols, Arsht & Tunnell; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Osmotica Pharmaceutical US LLC v. Adamas Pharmaceuticals, Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Osmotica Pharmaceutical US LLC v. Adamas Pharmaceuticals, Inc. (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 claim of U.S. Patent Nos. 8,389,578 (“the ’578 patent”); 8,741,343 (“the ’343 patent”); 8,796,337 (“…now U.S. Patent No. 8,389,578. The ’578 patent claims the benefit to U.S. Provisional Patent Application…now U.S. Patent No. 8,389,578. The ’578 patent claims the benefit to U.S. Provisional Patent Application… now U.S. Patent No. 8,389,578. The ’578 patent claims benefit to U.S. Provisional Patent Application… now U.S. Patent No. 8,389,578. The ’578 patent claims benefit to U.S. Provisional Patent Application External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Baxter
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.